Expertise in
10
conditions

Dr. Michael A. Finan

Oncology
Singing River Health System
2101 Highway 90, 
Gautier, MS 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Expertise in
10
conditions
Singing River Health System
2101 Highway 90, 
Gautier, MS 

Overview

Michael Finan is an Oncologist practicing medicine in Gautier, Mississippi.

Dr. Finan is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Ovarian Cancer, Virilizing Ovarian Tumor, Testicular Yolk Sac Tumor, Bladder Reconstruction, and Splenectomy.

He is actively involved in clinical research, co-authoring 15 peer reviewed articles and participating in 15 clinical trials. Dr. Finan is currently accepting new patients.

Specialties

Oncology

Licenses

Obstetrics & Gynecology in AL

Hospital Affiliations

Singing River Health System
Singing River Gulfport
Memorial Hospital At Gulfport

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Magnolia Health
  • HMO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

Singing River Health System
2101 Highway 90, Gautier, MS 39553
Other Locations
Singing River Health System
2809 Denny Ave, Pascagoula, MS 39581

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
Enrollment Status: Recruiting
Publish Date: September 02, 2026
Intervention Type: Procedure, Other
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: September 04, 2026
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2026
Intervention Type: Other
Study Phase: Phase 3
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Dabrafenib Mesylate, Ipilimumab, Nivolumab, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 3
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Carboplatin, Pembrolizumab, Pemetrexed
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Other, Procedure, Drug
Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 3
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
Enrollment Status: Active_not_recruiting
Publish Date: July 10, 2026
Intervention Type: Procedure, Biological, Drug, Radiation
Study Drugs: Docetaxel, Nab-Paclitaxel, Paclitaxel, Pertuzumab, Trastuzumab, Trastuzumab Emtansine
Study Phase: Phase 2
View 9 Less Clinical Trials

15 Total Publications

A novel proteomic-based screening method for ovarian cancer using cervicovaginal fluids: A window into the abdomen.
A novel proteomic-based screening method for ovarian cancer using cervicovaginal fluids: A window into the abdomen.
Journal: Gynecologic oncology
Published: June 30, 2021
Similar Doctors
Expertise in
28
conditions
Expertise in
28
conditions
Referral may be required

Singing River Health System

2809 Denny Ave, 
Pascagoula, MS 
 (6.6 miles away)
228-809-5251
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Techksell Washington is an Oncologist practicing medicine in Pascagoula, Mississippi. Dr. Washington is highly rated in 28 conditions, according to our data. Her clinical expertise encompasses Angiosarcoma, Paget Disease of the Breast, Inflammatory Breast Cancer, and Multicentric Castleman Disease (MCD). Dr. Washington is currently accepting new patients.

Expertise in
48
conditions
Expertise in
48
conditions
Referral may be required

Brian E. Persing,MD

2809 Denny Ave, 
Pascagoula, MS 
 (6.6 miles away)
228-809-5251
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Brian Persing is an Oncologist practicing medicine in Pascagoula, Mississippi. Dr. Persing is highly rated in 48 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Pleuropulmonary Blastoma, Small Cell Lung Cancer (SCLC), and Adult Soft Tissue Sarcoma. Dr. Persing is currently accepting new patients.

Expertise in
17
conditions
Expertise in
17
conditions
Referral may be required

Singing River Health System

2101 Highway 90, 
Gautier, MS 
 (0.1 miles away)
228-809-2057
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

James Clarkson is an Oncologist practicing medicine in Gautier, Mississippi. Dr. Clarkson is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Anal Cancer, Breast Cancer, Familial Colorectal Cancer, and Paget Disease of the Breast. Dr. Clarkson is currently accepting new patients.

Frequently Asked Questions about Dr. Michael A. Finan

How do I make an appointment with Dr. Michael A. Finan?

You can book an appointment with Dr. Michael A. Finan by calling their office at 228-809-5251. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Michael A. Finan a top-rated expert for Ovarian Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Michael A. Finan is classified as an Distinguished expert for Ovarian Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Michael A. Finan specialize in?

While Dr. Michael A. Finan is a Oncology, they have specific expertise in Ovarian Cancer, Virilizing Ovarian Tumor, and Testicular Yolk Sac Tumor. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Michael A. Finan participate in research or clinical trials?

Yes. Dr. Michael A. Finan has published 15 articles and abstracts on conditions like Ovarian Cancer. You can view a list of Dr. Michael A. Finan's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Michael A. Finan accept my insurance?

Dr. Michael A. Finan accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 228-809-5251 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Finan's expertise for a condition
ConditionClose
    View All 10 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile